Biotechnology
Johnson and Johnson's $1 billion acquisition of Firefly Bio signals a major shift in cancer drug design. We explore what degrader antibody conjugates mean for the future of oncology and why this bet matters for patients with KRAS-driven cancers.
Pharmaceuticals
Data from Boehringer Ingelheim's survodutide Phase 3 trials reveals a mechanistically distinct approach to obesity treatment, with exceptional reductions in visceral and liver fat that reframe what obesity drugs can achieve.
Policy
When Eli Lilly announced it was cutting its planned German investment in half, the news landed with the weight of a verdict. Together with Boehringer Ingelheim's cancellation of 900 million euros in spending, more than $2 billion in future investment was pulled from Germany in a single day.
Pharmaceuticals
Pfizer's $10.5 billion deal with China's Innovent Biologics signals a major strategic shift in how Western pharma is leveraging Chinese biotech innovation in oncology.
Biotechnology
Eli Lilly is making a $4 billion commitment to rebuild its infectious disease portfolio from scratch, acquiring three vaccine developers and signaling a strategic pivot away from its GLP-1 dominance.
Biotechnology
Roche's $1.05 billion acquisition of PathAI signals that AI-powered digital pathology is becoming as strategically important as drug development itself in precision oncology.
Biotechnology
Bayer's $2.45 billion acquisition of Perfuse Therapeutics signals a strategic shift in ophthalmology toward disease-modifying treatments that could reverse vision loss in glaucoma and diabetic retinopathy—conditions affecting over 200 million people worldwide.
Biotechnology
Cytokinetics' ACACIA-HCM Phase 3 trial just delivered the first statistically significant win in non-obstructive HCM. Here is what the data mean, why the disease has been so hard to treat, and what comes next for aficamten and the field.
Biotechnology
UCB's $2.2 billion acquisition of Candid Therapeutics signals a fundamental shift in autoimmune treatment strategy. T-cell engagers could reshape immunology the way CAR-T transformed oncology.
Pharmaceuticals
Sun Pharmaceutical's $11.75 billion acquisition of Organon marks a watershed moment in global pharmaceutical consolidation. The deal reveals how Indian drugmakers are evolving from generics suppliers into genuine global players, while exposing the structural pressures reshaping the industry.
Biotechnology
Kailera Therapeutics' record-breaking $625 million IPO marks a pivotal moment in the obesity drug market, signaling investor confidence in Chinese-origin drug pipelines and validating a new model for biotech fundraising.
Pharmaceuticals
Novo Nordisk launched Wegovy HD at $399 per month, undercutting Lilly's Zepbound by $50. The move signals a new phase in the GLP-1 market where pricing strategy and clinical differentiation are becoming inseparable.